Gutscheinbedingungen

**Gültig bis 25.06.2026 auf fremdsprachige Bücher online auf thalia.at und in der Thalia App. Einzelne Artikel können ausgeschlossen sein. Ausgenommen sind preisgebundene Artikel & eBooks. Pro Einkauf einmal einlösbar. Click & Collect nur bei Onlinevorabzahlung möglich. Keine Barauszahlung. Nicht kombinierbar mit anderen Aktionen und Gutscheinen. Gutschein wird auf max. 500€ Bestellwert angerechnet. Nicht gültig für Geschenkkarten, Versandkosten und Services.

Produktbild: Advancements in Personalized Cellular Immunotherapy
Vorbesteller Neu

Advancements in Personalized Cellular Immunotherapy A Comprehensive Guide to Cancer Treatment

184,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

01.08.2026

Herausgeber

Arun Kumar Singh + weitere

Verlag

Elsevier

Seitenzahl

320

Maße (L/B)

23,5/19,1 cm

Gewicht

450 g

Sprache

Englisch

ISBN

978-0-443-27731-3

Beschreibung

Portrait

Arun Kumar Singh completed his Master of Pharmacy (M. Pharm) in Pharmaceutics from Galgotias University, Greater Noida, India. He is currently an Assistant Professor in the Department of Pharmacy at Vivekanand Global University, where he is actively engaged in teaching and research.

His research interests encompass various emerging and interdisciplinary fields, including nano-formulation, blockchain technology, the Internet of Things (IoT), machine learning, cancer biology, artificial intelligence, big data analytics, and neuroscience. Demonstrating a strong commitment to academic excellence, Mr. Singh has made significant contributions to the scientific community.

Dr. Murali Yallapu is a tenured Associate Professor at the University of Texas Rio Grande Valley's School of Medicine, specializing in Immunology, Microbiology, and Oncology and a member of the South Texas Center of Excellence in Cancer Research. Dr. Yallapu received the "Prof. A. Kameswara Rao's Gold Medal‐1999" and completed postdoctoral training in materials science, drug delivery, nanomedicine, and cancer biology at institutions including Cleveland Clinic and University of Nebraska Medical Center. Before joining UTRGV, he was an Assistant Professor at the University of Tennessee Health Science Center. Dr. Yallapu serves on editorial boards for various journals related to drug delivery, nanotechnology, and cancer, and is an ad-hoc reviewer for the NIH and other funding agencies. He has published over 190 peer-reviewed articles and reviews, with his work cited over 16,156 times. His primary research focuses on developing nanomaterials for enhanced therapeutic potential and cancer immunotherapy.

Dr.Ciniraj is presently working as an Associate Professor at Medical College Thiruvananthapuram, Kerala, India, one of the largest multispecialty tertiary care hospitals in southern India. He undertakes teaching courses in oncology for undergraduate and postgraduate students. As a permanent faculty member appointed by the government of Kerala State, he is actively involved in patient care, curriculum development, teaching and evaluation, and clinical research. He actively participates in national and international conferences and institutional research methodology workshops. Currently, he undertakes research projects in clinical oncology at multiple government institutions as primary investigator. He also works as a guide to postgraduate thesis and assists them in their research work. He has a deep interest in oncology research and has published a few original research articles in clinical oncology, which are indexed in Scopus and PubMed. He has reviewed over 100 medical articles for leading publishers, including Elsevier, Springer, and British Medical Journal

Dr. Pranav Kumar Prabhakar is currently working as a Professor in the Department of Biotechnology at Nagaland University, Kohima, Nagaland, India. He has been listed among the World’s Top 2% Scientists (as published by Stanford University, USA, in 2021, 2022, 2023, and 2024). He earned his PhD in Biotechnology from IIT Madras. His primary research interests include elucidating molecular mechanisms and strategies for oral insulin delivery and mimicking signaling pathways in metabolic disorders (diabetes) using natural products. He is a member of the Royal Society of Chemistry and the Asia-Pacific Chemical, Biological & Environmental Engineering Society. He also serves as an editorial board member and reviewer for several reputed national and international journals. Dr. Pranav has received various honors, including a travel grant to attend ATTD 2009 in Greece, sponsored by the Indian Institute of Technology Madras and the Council for Scientific and Industrial Research (CSIR), and approved by the Department of Science and Technology (DST). He has published over 115 research articles in journals, authored or edited 17 books, contributed more than 40 book chapters, and delivered 9 oral and poster presentations at scientific meetings.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

01.08.2026

Herausgeber

Verlag

Elsevier

Seitenzahl

320

Maße (L/B)

23,5/19,1 cm

Gewicht

450 g

Sprache

Englisch

ISBN

978-0-443-27731-3

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Kundinnen und Kunden meinen

0 Bewertungen

Informationen zu Bewertungen

Zur Abgabe einer Bewertung ist eine Anmeldung im Konto notwendig. Die Authentizität der Bewertungen wird von uns nicht überprüft. Wir behalten uns vor, Bewertungstexte, die unseren Richtlinien widersprechen, entsprechend zu kürzen oder zu löschen.

Die Bewertungen sind nach Format, Anzahl Sterne und Datum sortiert.

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kund*innen durch Ihre Meinung

Kundinnen und Kunden meinen

0 Bewertungen filtern

  • Produktbild: Advancements in Personalized Cellular Immunotherapy
  • 1. Introduction to Personalized Cellular Immunotherapy
    2. Understanding the therapeutic significance of tumor-infiltrating immune cells and their characteristics: a historical overview of cancer immunotherapy
    3. A groundbreaking development in cancer treatment: chimeric antigen receptor CART-cell therapy
    4. Recent Progress in CAR-T Cell Therapy for B Cell Cancers with Resistant Tissues
    5. Targeting the tumor vasculature using mesenchymal stem cells in cancer therapy: new perspectives
    6. The use of oncolytic viruses delivered by mesenchymal stromal cells in immunotherapy for the treatment of metastatic tumors
    7. Cancer Treatment Advancements in the Era of Immune Checkpoint Inhibitors via Cellular Immunotherapies
    8. The future of cancer immunotherapy: combining gene and cellular approaches
    9. Platelet Shielding of Cancer Cells: Implications for Immunotherapy Strategies
    10. Cancer Cell-Platelet Interactions: Harnessing Therapeutic Opportunities in Cancer Treatment
    11. Myeloid-Derived Suppressor Cells: A Promising Target for Anticancer Immunotherapy
    12. Utilizing Nanomedicines to Modulate Myeloid-Derived Suppressor Cells: Enhancing Cancer Immunotherapy
    13. Unlocking the Potential of Macrophages: Advancements in Cellular Immunotherapy
    14. Combination therapy: a new strategy to manage cancer
    15. Future perspective of cellular immunotherapy in cancer treatment